☆ 4.6 Article

Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myeloma

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

In Multiple Myeloma, High-Risk Secondary Genetic Events Observed at Relapse Are Present From Diagnosis in Tiny, Undetectable Subclonal Populations

Romain Lannes et al.

Summary: Using single-cell genomics, it was found that high-risk events in multiple myeloma (MM) patients are often missed at diagnosis and only selected at relapse. This suggests the need for more aggressive treatment at diagnosis to prevent these aggressive cells from becoming dominant clones.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Oncology

Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up

Thomas Martin et al.

Summary: PURPOSECARTITUDE-1, a phase Ib/II study, evaluated the safety and efficacy of Ciltacabtagene Autoleucel in heavily treated patients with relapsed/refractory multiple myeloma. The study showed early, deep, and durable responses at 12 months, with updated results at 2 years. Patients received a single infusion of Ciltacabtagene Autoleucel and responses were assessed.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Hematology

Prognostic significance of acquired 1q22 gain in multiple myeloma

Hadiyah Y. Audil et al.

Summary: Acquisition of 1q22 gain in multiple myeloma patients is associated with reduced overall survival. Presence of high-risk FISH abnormalities at baseline increases the risk of acquiring 1q22 gain.

AMERICAN JOURNAL OF HEMATOLOGY (2022)

Add to Collection

Letter Oncology

Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma

Saurabh Zanwar et al.

LEUKEMIA (2022)

Add to Collection

Review Oncology

Extramedullary disease in multiple myeloma: a systematic literature review

Joan Blade et al.

Summary: Extramedullary involvement is an aggressive form of multiple myeloma, with varied typical sites and incidence rates. Patients with EMD have poor prognosis and lower treatment efficacy. The lack of prospective studies limits strong recommendations for treatment approaches.

BLOOD CANCER JOURNAL (2022)

Add to Collection

Article Cell Biology

Plasma cell dynamics in the bone marrow niche

Zachary Benet et al.

Summary: Intravital imaging revealed that bone marrow plasma cells (PCs) exhibit a unique migration pattern characterized by intermittent high motility periods and longer stretches of confined migration or arrest. The study showed that APRIL promotes cluster formation and overall PC motility in the bone marrow.

CELL REPORTS (2021)

Add to Collection

Article Oncology

Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage

Carlos Fernandez de Larrea et al.

Summary: Prompt identification and effective treatment of primary plasma cell leukemia (PCL) are crucial due to its consistently poor prognosis. Revisiting the diagnosis of PCL based on the presence of circulating plasma cells in peripheral blood is essential for defining this high-risk disease.

BLOOD CANCER JOURNAL (2021)

Add to Collection

Review Hematology

Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations

Laura Rosinol et al.

Summary: This review identifies two types of soft-tissue involvement in multiple myeloma: EMD and PS. EMD disease is associated with high-risk cytogenetics, therapy resistance, and worse prognosis. For patients with PS involvement, a proteasome inhibitor-based regimen may be the best option.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

Add to Collection

Article Immunology

Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials

Yimei Que et al.

Summary: Based on the analysis of clinical trial results of anti-BCMA CAR-T cell therapy, it was found that patients with extramedullary multiple myeloma could benefit from this treatment in terms of safety, efficacy, and pharmacokinetics, although they had shorter overall survival and progression-free survival compared to non-extramedullary multiple myeloma patients.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Ciltacabtagene autoleucel, a B-cell maturation antigendirected chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

Jesus G. Berdeja et al.

Summary: The study aimed to evaluate the safety and clinical activity of cilta-cel in patients with relapsed or refractory multiple myeloma, and the results showed that cilta-cel treatment achieved good efficacy and safety with short treatment duration, deep response, and long duration of response.

LANCET (2021)

Add to Collection

Review Oncology

Extramedullary multiple myeloma

Manisha Bhutani et al.

LEUKEMIA (2020)

Add to Collection

Article Oncology

Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results.

Nikhil C. Munshi et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Hematology

PD-L1, LAG3, and HLA-DR are increasingly expressed during smoldering myeloma progression

Alberto Mussetti et al.

ANNALS OF HEMATOLOGY (2019)

Add to Collection

Review Hematology

Extramedullary disease in multiple myeloma - controversies and future directions

Sabina Sevcikova et al.

BLOOD REVIEWS (2019)

Add to Collection

Review Immunology

Survival of Long-Lived Plasma Cells (LLPC): Piecing Together the Puzzle

Shivana M. Lightman et al.

FRONTIERS IN IMMUNOLOGY (2019)

Add to Collection

Article Hematology

Impact of acquired del(17p) in multiple myeloma

Arjun Lakshman et al.

BLOOD ADVANCES (2019)

Add to Collection

Article Immunology

CXCR4-CXCL12 interaction is important for plasma cell homing and survival in NZB/W mice

Qingyu Cheng et al.

EUROPEAN JOURNAL OF IMMUNOLOGY (2018)

Add to Collection

Article Oncology

Multiple myeloma clonal evolution in homogeneously treated patients

Jill Corre et al.

LEUKEMIA (2018)

Add to Collection

Meeting Abstract Hematology

Preclinical Activity of Novel MCL1 Inhibitor AZD5991 in Multiple Myeloma

Shannon M. Matulis et al.

BLOOD (2018)

Add to Collection

Review Oncology

Genomic complexity of multiple myeloma and its clinical implications

Salomon Manier et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2017)

Add to Collection

Article Multidisciplinary Sciences

Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing

L. Rasche et al.

NATURE COMMUNICATIONS (2017)

Add to Collection

Article Oncology

T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of Immunotherapy

David J. Chung et al.

CANCER IMMUNOLOGY RESEARCH (2016)

Add to Collection

Review Hematology

Myeloid-derived suppressor cells: The green light for myeloma immune escape

Ehsan Malek et al.

BLOOD REVIEWS (2016)

Add to Collection

Article Oncology

Biological and Clinical Implications of Clonal Heterogeneity and Clonal Evolution in Multiple Myeloma

Giada Bianchi et al.

CURRENT CANCER THERAPY REVIEWS (2014)

Add to Collection

Review Oncology

Extramedullary multiple myeloma

Matthew Weinstock et al.

LEUKEMIA & LYMPHOMA (2013)

Add to Collection

Article Hematology

Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents

Saad Z. Usmani et al.

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)

Add to Collection

Article Medicine, Research & Experimental

Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma

Giuseppina Bonanno et al.

JOURNAL OF TRANSLATIONAL MEDICINE (2012)

Add to Collection

Review Oncology

The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies

A. Kalff et al.

BLOOD CANCER JOURNAL (2012)

Add to Collection

Article Oncology

Soft-Tissue Plasmacytomas in Multiple Myeloma: Incidence, Mechanisms of Extramedullary Spread, and Treatment Approach

Joan Blade et al.

JOURNAL OF CLINICAL ONCOLOGY (2011)

Add to Collection

Article Oncology

Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients

M. Varettoni et al.

ANNALS OF ONCOLOGY (2010)

Add to Collection

Article Oncology

Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance

Lei Shi et al.

ONCOTARGET (2010)

Add to Collection

© Peeref 2019-2024. All rights reserved.